Charlotte’s Web (TSE:CWEB) recently held its fourth-quarter 2025 earnings call, where CEO Bill Morachnick discussed significant developments for the company. He highlighted a strategic balance sheet restructuring with British American Tobacco (BAT), a new distribution pathway for hemp-derived CBD products in the Medicare space, and advancements in a clinical program with DeFloria.
Morachnick revealed that Charlotte’s Web entered into a financial transaction with BAT related to BAT’s convertible loan note. The deal involved converting BAT’s $55 million convertible debenture, along with accrued interest, into Charlotte’s Web common shares at a conversion price of CAD 0.94 per share. Additionally, a new $10 million equity investment was made through a private placement. This move was described as eliminating the company’s largest balance sheet liability and avoiding significant future interest payments.
Following the completion of the transaction, BAT will hold around 40% of the company on a non-diluted basis, with a combined equity commitment of approximately $75 million. CFO Erika Lind emphasized that this deal was transformational for Charlotte’s Web’s balance sheet, eliminating a substantial debt burden while injecting working capital into the company.
A key growth opportunity highlighted during the earnings call was the Center for Medicare and Medicaid Innovation (CMMI) pilot program. This initiative allows seniors to access CBD products through a federally authorized Medicare pilot, with recent guidance establishing the Substance Access Beneficiary Engagement Incentive (Substance Access BEI) as the mechanism for the program. Participating organizations, including existing healthcare entities enrolled in CMS innovation models, can begin offering the Substance Access BEI starting April 1, 2026.
On the revenue front, management declined to provide specific guidance but mentioned a gradual revenue build over the next 12 to 18 months as the Medicare pilot program gains traction. Morachnick also discussed a longer-term Medicare pathway that could potentially include hemp-derived CBD products in Medicare Advantage plans.
Additionally, the company is involved in a pharmaceutical-adjacent clinical program called DeFloria, focused on developing a treatment for irritability associated with autism spectrum disorder. Phase II clinical trials are set to begin mid-year, with Charlotte’s Web holding exclusive commercial manufacturing rights if the product receives FDA approval.
In terms of financial performance, Charlotte’s Web reported consolidated net revenue of $13.3 million for Q4 2025, with a sequential increase of 15.8%. Gross profit was $5.0 million, impacted by a one-time inventory charge, while SG&A expenses totaled $10.6 million for the quarter. The company posted a net loss of $11.4 million for Q4.
Looking ahead, Charlotte’s Web aims to leverage its strategic partnerships, capitalize on the Medicare pilot program, and continue its focus on product innovation and clinical development. The company remains optimistic about its growth prospects in the evolving CBD wellness market.
